(Q50224622)

English

Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study

scientific article published in August 2017

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 February 2018

http://europepmc.org/abstract/MED/28870107

Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 February 2018

http://europepmc.org/abstract/MED/28870107

multiple sclerosis

0 references

relapsing-remitting multiple sclerosis

1 reference

based on heuristic

inferred from title

6

object named as

Giancarlo Comi

1 reference

Europe PubMed Central

PubMed publication ID

27 February 2018

Gavin Giovannoni

1

object named as

Gavin Giovannoni

1 reference

Europe PubMed Central

PubMed publication ID

27 February 2018

Per Soelberg Sørensen

2

object named as

Per Soelberg Sorensen

1 reference

Europe PubMed Central

PubMed publication ID

27 February 2018

author name string

Stuart Cook

3

1 reference

Europe PubMed Central

PubMed publication ID

27 February 2018

http://europepmc.org/abstract/MED/28870107

Kottil Rammohan

4

1 reference

Europe PubMed Central

PubMed publication ID

27 February 2018

http://europepmc.org/abstract/MED/28870107

Peter Rieckmann

5

1 reference

Europe PubMed Central

PubMed publication ID

27 February 2018

http://europepmc.org/abstract/MED/28870107

Fernando Dangond

7

1 reference

Europe PubMed Central

PubMed publication ID

27 February 2018

http://europepmc.org/abstract/MED/28870107

Abidemi K Adeniji

8

1 reference

Europe PubMed Central

PubMed publication ID

27 February 2018

http://europepmc.org/abstract/MED/28870107

Patrick Vermersch

9

1 reference

Europe PubMed Central

PubMed publication ID

27 February 2018

http://europepmc.org/abstract/MED/28870107

publication date

1 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

27 February 2018

http://europepmc.org/abstract/MED/28870107

Multiple Sclerosis Journal

1 reference

Europe PubMed Central

PubMed publication ID

27 February 2018

http://europepmc.org/abstract/MED/28870107

1352458517727603

1 reference

Europe PubMed Central

PubMed publication ID

27 February 2018

http://europepmc.org/abstract/MED/28870107

Cladribine (2-chlorodeoxyadenosine)

1 reference

https://api.crossref.org/works/10.1177%2F1352458517727603

21 January 2018

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458517727603

21 January 2018

The treatment of chronic progressive multiple sclerosis with cladribine

1 reference

https://api.crossref.org/works/10.1177%2F1352458517727603

21 January 2018

Progressive multifocal leukoencephalopathy in a patient with systemic mastocytosis treated with cladribine.

1 reference

https://api.crossref.org/works/10.1177%2F1352458517727603

21 January 2018

No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine

1 reference

https://api.crossref.org/works/10.1177%2F1352458517727603

21 January 2018

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1177%2F1352458517727603

21 January 2018

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458517727603

21 January 2018

Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study

1 reference

https://api.crossref.org/works/10.1177%2F1352458517727603

21 January 2018

The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation

1 reference

https://api.crossref.org/works/10.1177%2F1352458517727603

21 January 2018

Identifiers

10.1177/1352458517727603

1 reference

Europe PubMed Central

PubMed publication ID

27 February 2018

http://europepmc.org/abstract/MED/28870107

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 February 2018

http://europepmc.org/abstract/MED/28870107

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50224622&oldid=2246028778"